Showing papers in "Journal of Thrombosis and Haemostasis in 2011"

TL;DR: Platelets provide a procoagulant surface facilitating amplification of cancer‐related coagulation, and can be recruited to shroud tumor cells, thereby shielding them from immune responses, and facilitate cancer growth and dissemination.

TL;DR: Prophylaxis was more effective when started early (≤36 months), with patients having fewer joint bleeds and arthropathy in children with hemophilia, particularly when it is initiated early in life.

TL;DR: From neutrophil extracellular traps release to thrombosis: an overshooting host‐defense mechanism?

TL;DR: The analysis provides a thorough PK characterization of dabigatran in the AF patient population from RE‐LY and none of the covariates investigated, with the exception of renal function, warrants dose adjustment.

TL;DR: Recent experimental evidence now suggests that early platelet adhesion and activation events, orchestrate a ‘thrombo‐inflammatory’ cascade in this setting, whereas platelet aggregation and thrombus formation are not required.

TL;DR: Patients with PE selected for outpatient treatment with predefined criteria can be treated with anticoagulants on an outpatient basis, as shown in this prospective cohort study of patients with objectively proven acute PE.

TL;DR: The APTT‐based assay for APC resistance is affected in a dose‐dependent manner whereas an assay based on the activation of coagulation at the prothrombinase level was unaffected.

TL;DR: A new scheme (CHA2DS2‐VASc) may discriminate those at truly low risk and minimize classification of subjects as intermediate/moderate risk and improve decision‐making for thromboprophylaxis in patients with AF.

TL;DR: The serpin structure and general mechanism of protease inhibition are introduced, and it is illustrated, using recent crystallographic and biochemical data on antithrombin (AT), how serpin activity can be modulated by cofactors.

TL;DR: The possible consequences that are discussed herein include whether cirrhosis is a condition associated with increased risk of venous thromboembolism or portal vein thrombosis; the hypercoagulability associated with Cirrhosis has any other role outside coagulation (i.e. progression of liver fibrosis); and anticoagulation should be used in cir rhosis.

TL;DR: The variety of interactions between platelets and bacteria is reviewed, and the potential for inhibiting these interactions in diseases such as infective endocarditis and sepsis is looked at.

TL;DR: Polystyrene and silica microspheres with higher refractive indices forward scattered more light with a wavelength of 488 nm for a given size microparticle than did lipid vesicles or platelets, and the Apogee A40 was able to resolve size differences in polystyrene microsphere down to 0.4 μm.

TL;DR: It is proposed that modulating these newly described platelet functions may help treat haemorrhage as well as treat cancer by increasing the efficacy of drug delivery to tumours.

TL;DR: A ride with ferric chloride is described in this issue of This issue, pp 776–8.

TL;DR: The overall physiological result of this is to promote coagulation through enhancing initiation, suppressing negative regulation and impairing fibrin removal.

TL;DR: In an unselected nationwide cohort of hospitalized patients with atrial fibrillation, the HAS‐BLED score performs similarly to HEMORR2HAGES in predicting bleeding risk but HAS‐ BLED is much simpler and easier to use in everyday clinical practise.

TL;DR: Understanding the reasons for racial differences in VTE will help providers develop strategies to minimize VTE in all populations, as risk factors for thrombosis are applicable to more people, as obesity increases in prevalence in the developing world, and as surveillance systems for VTE improve, VTE may increase in previously low‐risk populations.

TL;DR: CRT risk is increased with use of PICCs, previous history of DVT, subclavian venipuncture insertion technique and improper positioning of the catheter tip, and these factors may be useful for risk stratifying patients to select those for thromboprophylaxis.

TL;DR: Historical aspects of platelet membrane asymmetry characterization are recalled, the mechanisms and roles of PS exposure following platelet activation are summarized and the recent identification of TMEM16F and its significance in the scrambling process are discussed.

TL;DR: Results indicate that ‘the late‐onset phenotype’ of USS is formed with ethnic specificity, and two of these three males developed sudden overt TTP when they were 55 and 63’years old, respectively.

TL;DR: This paper presents a meta-analyses of the prophylactic and motivational properties of beta-blocker chemoreception in response to the presence or absence of thrombosis in mice.

TL;DR: This represents the largest epidemiologic study that demonstrates a lower incidence of VTE in Asian compared with Western populations; however, it also demonstrates a yearly increasing incidence ofVTE in the Korean population.

TL;DR: A three‐dimensional structure of FXIIIa was developed by molecular modeling, which shows good agreement with the drastic structural changes demonstrated by biochemical studies, and the structural requirements for enzyme‐substrate interaction and for transglutaminase activity are reviewed.

TL;DR: The function of β(2)-Glycoprotein I (β(2) -GPI has long been an enigma as mentioned in this paper, and the current knowledge on this protein is summarized in this review.

TL;DR: MPs from platelets and monocytes differentially modulate clot formation, structure and stability, suggesting unique contributions to thrombosis.

TL;DR: Given their immunophenotypic similarity, the newly characterized Mon2 population may represent the previously reported pluripotent progenitor/pro‐angiogenic monocytes.

TL;DR: The benefit of various types of thromboprophylaxis is difficult to quantify in patients with MM receiving immunomodulatory therapy, especially in those receiving lenalidomide‐based therapy or who have previously treated MM.

TL;DR: Warkentin et al. as discussed by the authors proposed a conceptual framework for diagnosis of heparin-induced thrombocytopenia using laboratory testing for the International Society on Thrombosis and Haemostasis.

TL;DR: P2Y12 receptor blockade alone causes inhibition of platelet aggregation that is little enhanced by aspirin, and the antiaggregatory effects of PAM were associated with reductions in the platelet release of both TXA2 and ATP + ADP.

TL;DR: A new generation of anticoagulants with a greater specificity towards activated coagulation factors as well as new antiplatelet agents have been introduced and these drugs show promising results in clinical studies, although experimental studies show hopeful results for some of these agents.